PUBLISHER: IMARC | PRODUCT CODE: 1467759
PUBLISHER: IMARC | PRODUCT CODE: 1467759
The global transfection reagents and equipment market size reached US$ 971.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,766.9 Million by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032.
Transfection reagents and equipment help modulate gene expression in eukaryotic cells in vitro and in vivo. They allow researchers to generate stable cell lines and introduce deoxyribonucleic acid (DNA) plasmids possessing gene inserts for expression and small interfering RNA (siRNA). They are currently being used as viable analytical tools for protein synthesis, cell growth and development, and facilitating the study of genetic functions. Besides this, as they provide cost-effective and rapid production of recombinant human therapeutic proteins in sufficient quantities, transfection reagents and equipment are also gaining traction in producing r-proteins, antibodies, and viral vectors for vaccines.
Due to the outbreak of coronavirus disease (COVID-19) globally, governing agencies of numerous countries are focusing on accelerating the vaccination drive. However, due to the emergence of new variants, the protection and immunity that these vaccines provide are short-lived. As a result, there is a rise in the need of transfection reagents and equipment to develop innovative strategies or alternatively repurpose existing treatments to fight against virus infection. Apart from this, rapid detection of new cancer variants, coupled with the escalating demand for precision medicine and high-quality oncology care, are driving the adoption of transfection reagents and equipment in cancer research and drug development. Moreover, the emerging use of gene therapies to treat rare diseases caused by genetic problems is impelling the market growth. Furthermore, due to the growing number of fatal road accidents across the globe, there is a significant rise in the demand for tissue engineering to develop functional substitutes for damaged tissues. This, in turn, is propelling the market growth. Besides this, recent advancements in transfection technologies, along with increasing investments in pharmaceutical and biotechnology sectors, are anticipated to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global transfection reagents and equipment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, technology, application and end user.
Reagents
Equipment
Biochemical Based Transfection
Physical Transfection
Viral-Vector Based Transfection
Biomedical Research
Protein Production
Therapeutic Delivery
Pharmaceutical and Biotechnology Companies
Academics and Research Institutes
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., Lonza Group AG, MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PerkinElmer Inc., Polyplus-transfection SA, Promega Corporation, PromoCell GmbH, Qiagen N.V. and Thermo Fisher Scientific Inc.